|
|
| (9 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
| {{DrugProjectFormSinglePage
| |
| |authorTag={{JS}}
| |
| |genericName=Doxazosin mesylate
| |
| |aOrAn=a
| |
| |drugClass=alpha-adrenergic blocker
| |
| |indication=[[benign prostatic hyperplasia]] ([[BPH]]) and [[hypertension]]
| |
| |adverseReactions=[[edema]], [[hypotension]], [[nausea]], [[dizziness]], [[headache]], [[somnolence]], [[vertigo]] and [[fatigue]]
| |
| |blackBoxWarningTitle=Warning Title
| |
| |blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content)
| |
| |fdaLIADAdult======BENIGN PROSTATIC HYPERPLASIA =====
| |
|
| |
|
| * Initial dose:
| |
|
| |
| :* ''1 mg once a day''
| |
|
| |
| * Depending on the patient's [[urodynamics]] and [[BPH]] symptomatology, dosage may be increased, with a recommended titration interval of 1-2 weeks, to:
| |
|
| |
| :*''2 mg once a day'', followed by ''4 mg once a day'' until the maximum dosage of ''8 mg once a day''.
| |
|
| |
| =====HYPERTENSION=====
| |
|
| |
| * Initial dose:
| |
|
| |
| :* ''1 mg once a day''
| |
|
| |
| * Depending on the patient's standing [[blood pressure]] response (based on measurements taken at 2–6 hours post-dose and 24 hours post-dose), dosage may then be increased to:
| |
|
| |
| :* ''2 mg once a day'', followed by ''4 mg once a day'', than ''8 mg once a day'' until the maximum dosage of ''16 mg once a day'' to achieve the desired reduction in [[blood pressure]].
| |
| |offLabelAdultGuideSupport======Condition 1=====
| |
|
| |
| * Developed by: (Organisation)
| |
|
| |
| * Class of Recommendation: (Class) (Link)
| |
|
| |
| * Strength of Evidence: (Category A/B/C) (Link)
| |
|
| |
| * Dosing Information/Recommendation
| |
|
| |
| :* (Dosage)
| |
|
| |
| =====Condition 2=====
| |
|
| |
| * Developed by: (Organisation)
| |
|
| |
| * Class of Recommendation: (Class) (Link)
| |
|
| |
| * Strength of Evidence: (Category A/B/C) (Link)
| |
|
| |
| * Dosing Information/Recommendation
| |
|
| |
| :* (Dosage)
| |
| |offLabelAdultNoGuideSupport======Condition 1=====
| |
|
| |
| * Dosing Information
| |
|
| |
| :* (Dosage)
| |
|
| |
| =====Condition 2=====
| |
|
| |
| * Dosing Information
| |
|
| |
| :* (Dosage)
| |
|
| |
| =====Condition 3=====
| |
|
| |
| * Dosing Information
| |
|
| |
| :* (Dosage)
| |
| |fdaLIADPed======Condition 1=====
| |
|
| |
| * Dosing Information
| |
|
| |
| :* (Dosage)
| |
|
| |
| =====Condition 2=====
| |
|
| |
| * Dosing Information
| |
|
| |
| :* (Dosage)
| |
| |offLabelPedGuideSupport======Condition 1=====
| |
|
| |
| * Developed by: (Organisation)
| |
|
| |
| * Class of Recommendation: (Class) (Link)
| |
|
| |
| * Strength of Evidence: (Category A/B/C) (Link)
| |
|
| |
| * Dosing Information/Recommendation
| |
|
| |
| :* (Dosage)
| |
|
| |
| =====Condition 2=====
| |
|
| |
| * Developed by: (Organisation)
| |
|
| |
| * Class of Recommendation: (Class) (Link)
| |
|
| |
| * Strength of Evidence: (Category A/B/C) (Link)
| |
|
| |
| * Dosing Information/Recommendation
| |
|
| |
| :* (Dosage)
| |
| |offLabelPedNoGuideSupport======Condition 1=====
| |
|
| |
| * Dosing Information
| |
|
| |
| :* (Dosage)
| |
|
| |
| =====Condition 2=====
| |
|
| |
| * Dosing Information
| |
|
| |
| :* (Dosage)
| |
|
| |
| =====Condition 3=====
| |
|
| |
| * Dosing Information
| |
|
| |
| :* (Dosage)
| |
| |contraindications=* Doxazosin tablets are contraindicated in patients with a known sensitivity to quinazolines (e.g., prazosin, terazosin), doxazosin, or any of the inert ingredients.
| |
| |warnings======Syncope and "First-dose" Effect=====
| |
|
| |
| * Doxazosin, like other alpha-adrenergic blocking agents, can cause marked [[hypotension]], especially in the upright position, with syncope and other postural symptoms such as dizziness. Marked orthostatic effects are most common with the first dose but can also occur when there is a dosage increase, or if therapy is interrupted for more than a few days. To decrease the likelihood of excessive hypotension and syncope, it is essential that treatment be initiated with the 1 mg dose. The 2 mg, 4 mg, and 8 mg tablets are not for initial therapy. Dosage should then be adjusted slowly with evaluations and increases in dose every two weeks to the recommended dose. Additional antihypertensive agents should be added with caution.
| |
|
| |
| * Patients being titrated with doxazosin should be cautioned to avoid situations where injury could result should syncope occur, during both the day and night.
| |
|
| |
| * If syncope occurs, the patient should be placed in a recumbent position and treated supportively as necessary.
| |
|
| |
| =====Priapism=====
| |
|
| |
| * Rarely (probably less frequently than once in every several thousand patients), alpha1 antagonists, including doxazosin, have been associated with priapism (painful penile erection, sustained for hours and unrelieved by sexual intercourse or masturbation). Because this condition can lead to permanent impotence if not promptly treated, patients must be advised about the seriousness of the condition.
| |
| |clinicalTrials=======Central Nervous System======
| |
|
| |
| : (list/description of adverse reactions)
| |
|
| |
| ======Cardiovascular======
| |
|
| |
| : (list/description of adverse reactions)
| |
|
| |
| ======Respiratory======
| |
|
| |
| : (list/description of adverse reactions)
| |
|
| |
| ======Gastrointestinal======
| |
|
| |
| : (list/description of adverse reactions)
| |
|
| |
| ======Hypersensitive Reactions======
| |
|
| |
| : (list/description of adverse reactions)
| |
|
| |
| ======Miscellaneous======
| |
|
| |
| : (list/description of adverse reactions)
| |
|
| |
| =====Condition 2=====
| |
|
| |
| ======Central Nervous System======
| |
|
| |
| : (list/description of adverse reactions)
| |
|
| |
| ======Cardiovascular======
| |
|
| |
| : (list/description of adverse reactions)
| |
|
| |
| ======Respiratory======
| |
|
| |
| : (list/description of adverse reactions)
| |
|
| |
| ======Gastrointestinal======
| |
|
| |
| : (list/description of adverse reactions)
| |
|
| |
| ======Hypersensitive Reactions======
| |
|
| |
| : (list/description of adverse reactions)
| |
|
| |
| ======Miscellaneous======
| |
|
| |
| : (list/description of adverse reactions)
| |
| |postmarketing=(Description)
| |
| |drugInteractions=* Drug 1
| |
| * Drug 2
| |
| * Drug 3
| |
| * Drug 4
| |
| * Drug 5
| |
|
| |
| =====Drug 1=====
| |
|
| |
| (Description)
| |
|
| |
| =====Drug 2=====
| |
|
| |
| (Description)
| |
|
| |
| =====Drug 3=====
| |
|
| |
| (Description)
| |
|
| |
| =====Drug 4=====
| |
|
| |
| (Description)
| |
|
| |
| =====Drug 5=====
| |
|
| |
| (Description)
| |
| |useInPregnancyFDA=(Description)
| |
| |useInPregnancyAUS=(Description)
| |
| |useInLaborDelivery=(Description)
| |
| |useInNursing=(Description)
| |
| |useInPed=(Description)
| |
| |useInGeri=(Description)
| |
| |useInGender=(Description)
| |
| |useInRace=(Description)
| |
| |useInRenalImpair=(Description)
| |
| |useInHepaticImpair=(Description)
| |
| |useInReproPotential=(Description)
| |
| |useInImmunocomp=(Description)
| |
| |othersTitle=Others
| |
| |useInOthers=(Description)
| |
| |administration=(Oral/Intravenous/etc)
| |
| |monitoring======Condition 1=====
| |
|
| |
| (Description regarding monitoring, from ''Warnings'' section)
| |
|
| |
| =====Condition 2=====
| |
|
| |
| (Description regarding monitoring, from ''Warnings'' section)
| |
|
| |
| =====Condition 3=====
| |
|
| |
| (Description regarding monitoring, from ''Warnings'' section)
| |
| |IVCompat====Solution===
| |
|
| |
| ====Compatible====
| |
|
| |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
|
| |
| ====Not Tested====
| |
|
| |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
|
| |
| ====Variable====
| |
|
| |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
|
| |
| ====Incompatible====
| |
|
| |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
|
| |
| ===Y-Site===
| |
|
| |
| ====Compatible====
| |
|
| |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
|
| |
| ====Not Tested====
| |
|
| |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
|
| |
| ====Variable====
| |
|
| |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
|
| |
| ====Incompatible====
| |
|
| |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
|
| |
| ===Admixture===
| |
|
| |
| ====Compatible====
| |
|
| |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
|
| |
| ====Not Tested====
| |
|
| |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
|
| |
| ====Variable====
| |
|
| |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
|
| |
| ====Incompatible====
| |
|
| |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
|
| |
| ===Syringe===
| |
|
| |
| ====Compatible====
| |
|
| |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
|
| |
| ====Not Tested====
| |
|
| |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
|
| |
| ====Variable====
| |
|
| |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
|
| |
| ====Incompatible====
| |
|
| |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
|
| |
| ===TPN/TNA===
| |
|
| |
| ====Compatible====
| |
|
| |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
|
| |
| ====Not Tested====
| |
|
| |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
|
| |
| ====Variable====
| |
|
| |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
|
| |
| ====Incompatible====
| |
|
| |
| * Solution 1
| |
| * Solution 2
| |
| * Solution 3
| |
| |overdose=* Experience with doxazosin overdosage is limited.
| |
| |drugBox={{Drugbox2
| |
| | verifiedrevid =
| |
| | IUPAC_name =
| |
| | image =
| |
| | drug_name =
| |
|
| |
| <!--Clinical data-->
| |
| | tradename =
| |
| | MedlinePlus =
| |
| | licence_US =
| |
| | pregnancy_AU =
| |
| | pregnancy_US =
| |
| | legal_status =
| |
| | routes_of_administration =
| |
|
| |
| <!--Pharmacokinetic data-->
| |
| | bioavailability =
| |
| | metabolism =
| |
| | elimination_half-life =
| |
| | excretion =
| |
|
| |
| <!--Identifiers-->
| |
| | CAS_number_Ref =
| |
| | CAS_number =
| |
| | ATC_prefix =
| |
| | ATC_suffix =
| |
| | PubChem =
| |
| | IUPHAR_ligand =
| |
| | DrugBank_Ref =
| |
| | DrugBank =
| |
| | ChemSpiderID_Ref =
| |
| | ChemSpiderID =
| |
| | UNII_Ref =
| |
| | UNII =
| |
| | KEGG_Ref =
| |
| | KEGG =
| |
| | ChEBI_Ref =
| |
| | ChEBI =
| |
| | ChEMBL_Ref =
| |
| | ChEMBL =
| |
|
| |
| <!--Chemical data-->
| |
| | C= | H= | N= | O=
| |
| | molecular_weight =
| |
| | smiles =
| |
| | InChI =
| |
| | InChIKey =
| |
| | StdInChI_Ref =
| |
| | StdInChI =
| |
| | StdInChIKey_Ref =
| |
| | StdInChIKey =
| |
| | melting_point =
| |
| }}
| |
| |mechAction=(Description)
| |
| |structure=(Description with picture)
| |
| |PD=(Description)
| |
| |PK=(Description)
| |
| |nonClinToxic=(Description)
| |
| |clinicalStudies======Condition 1=====
| |
|
| |
| (Description)
| |
|
| |
| =====Condition 2=====
| |
|
| |
| (Description)
| |
|
| |
| =====Condition 3=====
| |
|
| |
| (Description)
| |
| |howSupplied=(Description)
| |
| |fdaPatientInfo=(Patient Counseling Information)
| |
| |alcohol=Alcohol-Doxazonin sandbox interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
| |
| |lookAlike=* (Paired Confused Name 1a) — (Paired Confused Name 1b)
| |
| * (Paired Confused Name 2a) — (Paired Confused Name 2b)
| |
| * (Paired Confused Name 3a) — (Paired Confused Name 3b)
| |
| }}
| |